SCM
SNDX icon

Sterling Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Sterling Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6K Sell
710
-147
-17% -$3.19K ﹤0.01% 2109
2025
Q4 		$18K Buy
857
+271
+46% +$4.73K ﹤0.01% 2286
2025
Q3 		$9.02K Buy
586
+241
+70% +$3.15K ﹤0.01% 2540
2025
Q2 		$3.23K Buy
345
+261
+311% +$2.87K ﹤0.01% 2746
2025
Q1 		$1.03K Hold
84
– – ﹤0.01% 2807
2024
Q4 		$1.11K Hold
84
– – ﹤0.01% 2919
2024
Q3 		$1.62K Buy
+84
New +$1.74K ﹤0.01% 2291

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Sterling Capital Management's SNDX Position: Q1 2026 in Review

Sterling Capital Management reduced its Syndax Pharmaceuticals (SNDX) stake by 17% in Q1 2026, selling an estimated $3.19K and leaving 710 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2109.

Sterling Capital Management first reported a position in SNDX in Q3 2024 and has held it in 7 quarters since. The position peaked at $18K in Q4 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Sterling Capital Management held 710 shares of Syndax Pharmaceuticals worth $16.6K as of Q1 2026.
  • Sterling Capital Management sold 147 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.19K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2109 holding.
  • Sterling Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Syndax Pharmaceuticals position peaked at $18K in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.